November 21, 2017 News by Patricia Silva, PhD Oral Cannabidiol, PTL101, Meets Goals of Phase 1 Study as Possible Spasticity Treatment Results of aĀ Phase 1 clinical trial in healthy volunteers show thatĀ PTL101, an oral cannabidiol compound, is a safe and effectively delivered potential treatment ofĀ spasticity inĀ multiple sclerosis (MS)Ā and for conditions like epilepsy,Ā Harvest One CannabisĀ announced. These findings were published in the journalĀ Clinical Pharmacology in Drug Development, in the study…
November 16, 2016 News by Joana Fernandes, PhD Growing Approval of Cannabis Use in US Expands a Major Market, But Tensions Evident Voters in fourĀ U.S. states onĀ Nov. 8 chose to legalize the recreational use of marijuana, and those in three other states approved the medicinal use ofĀ cannabis ā all gains for pharmaceutical and other companies designing cannabis-based therapies for people with long-term chronic ills whose symptoms might be helped with these…
February 15, 2016 News by Patricia Inacio, PhD MS Campaign In UK Pushing for Broader Access to Medical Marijuana A new campaign called “EndĀ our pain” is asking people to sign a petition calling onĀ the U.K. to allow all patients with multiple sclerosis (MS) there to have access to medical cannabis as a treatment for MS symptoms, in keeping with countries Ā such as CanadaĀ and Germany, and a number…
October 23, 2015 News by Charles Moore Cannabis-Derived Sativex for MS-Related Spasticity Reported to Be Effective and Safe Barcelona, Spain-based, global pharma firm Almirall presented new clinical evidence at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) ā held in Barcelona October 7ā10, 2015 ā supporting the efficacy of its Sativex product, currently the only pharmaceutical medicine derived from cannabinoids…